These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 12798640)

  • 41. Recombinant low-seroprevalent adenoviral vectors Ad26 and Ad35 expressing the respiratory syncytial virus (RSV) fusion protein induce protective immunity against RSV infection in cotton rats.
    Widjojoatmodjo MN; Bogaert L; Meek B; Zahn R; Vellinga J; Custers J; Serroyen J; Radošević K; Schuitemaker H
    Vaccine; 2015 Oct; 33(41):5406-5414. PubMed ID: 26319741
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Nucleoprotein nanostructures combined with adjuvants adapted to the neonatal immune context: a candidate mucosal RSV vaccine.
    Remot A; Roux X; Dubuquoy C; Fix J; Bouet S; Moudjou M; Eléouët JF; Riffault S; Petit-Camurdan A
    PLoS One; 2012; 7(5):e37722. PubMed ID: 22655066
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Virus-like particle vaccine primes immune responses preventing inactivated-virus vaccine-enhanced disease against respiratory syncytial virus.
    Hwang HS; Lee YT; Kim KH; Ko EJ; Lee Y; Kwon YM; Kang SM
    Virology; 2017 Nov; 511():142-151. PubMed ID: 28846899
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Characterization of recombinant respiratory syncytial viruses with the region responsible for type 2 T-cell responses and pulmonary eosinophilia deleted from the attachment (G) protein.
    Elliott MB; Pryharski KS; Yu Q; Boutilier LA; Campeol N; Melville K; Laughlin TS; Gupta CK; Lerch RA; Randolph VB; LaPierre NA; Dack KM; Hancock GE
    J Virol; 2004 Aug; 78(16):8446-54. PubMed ID: 15280453
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Nucleic acid-based vaccines targeting respiratory syncytial virus: Delivering the goods.
    Smith TRF; Schultheis K; Broderick KE
    Hum Vaccin Immunother; 2017 Nov; 13(11):2626-2629. PubMed ID: 28881156
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Induction of mucosal and systemic immunity against respiratory syncytial virus by inactivated virus supplemented with TLR9 and NOD2 ligands.
    Shafique M; Wilschut J; de Haan A
    Vaccine; 2012 Jan; 30(3):597-606. PubMed ID: 22120195
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Lipopeptide-adjuvanted respiratory syncytial virus virosomes: A safe and immunogenic non-replicating vaccine formulation.
    Stegmann T; Kamphuis T; Meijerhof T; Goud E; de Haan A; Wilschut J
    Vaccine; 2010 Aug; 28(34):5543-50. PubMed ID: 20600502
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A single intranasal administration of virus-like particle vaccine induces an efficient protection for mice against human respiratory syncytial virus.
    Jiao YY; Fu YH; Yan YF; Hua Y; Ma Y; Zhang XJ; Song JD; Peng XL; Huang J; Hong T; He JS
    Antiviral Res; 2017 Aug; 144():57-69. PubMed ID: 28529001
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Virus-like particle vaccines containing F or F and G proteins confer protection against respiratory syncytial virus without pulmonary inflammation in cotton rats.
    Hwang HS; Kim KH; Lee Y; Lee YT; Ko EJ; Park S; Lee JS; Lee BC; Kwon YM; Moore ML; Kang SM
    Hum Vaccin Immunother; 2017 May; 13(5):1031-1039. PubMed ID: 28129031
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Murine host responses to respiratory syncytial virus (RSV) following intranasal administration of a Protollin-adjuvanted, epitope-enhanced recombinant G protein vaccine.
    Huang Y; Cyr SL; Burt DS; Anderson R
    J Clin Virol; 2009 Apr; 44(4):287-91. PubMed ID: 19233722
    [TBL] [Abstract][Full Text] [Related]  

  • 51. CD8 T cells inhibit respiratory syncytial virus (RSV) vaccine-enhanced disease.
    Olson MR; Varga SM
    J Immunol; 2007 Oct; 179(8):5415-24. PubMed ID: 17911628
    [TBL] [Abstract][Full Text] [Related]  

  • 52. IL-13 is sufficient for respiratory syncytial virus G glycoprotein-induced eosinophilia after respiratory syncytial virus challenge.
    Johnson TR; Parker RA; Johnson JE; Graham BS
    J Immunol; 2003 Feb; 170(4):2037-45. PubMed ID: 12574374
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Evaluation of truncated G protein delivered by live attenuated Salmonella as a vaccine against respiratory syncytial virus.
    Tian P; Xu D; Huang Z; Meng F; Fu J; Wei H; Chen T
    Microb Pathog; 2018 Feb; 115():299-303. PubMed ID: 29306006
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Respiratory syncytial virus vaccines for otitis media.
    Anderson LJ
    Vaccine; 2000 Dec; 19 Suppl 1():S59-65. PubMed ID: 11163465
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Partial Attenuation of Respiratory Syncytial Virus with a Deletion of a Small Hydrophobic Gene Is Associated with Elevated Interleukin-1β Responses.
    Russell RF; McDonald JU; Ivanova M; Zhong Z; Bukreyev A; Tregoning JS
    J Virol; 2015 Sep; 89(17):8974-81. PubMed ID: 26085154
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Experimental animal model for analyzing immunobiological responses following vaccination with formalin-inactivated respiratory syncytial virus.
    Sawada A; Nakayama T
    Microbiol Immunol; 2016 Apr; 60(4):234-42. PubMed ID: 26865035
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Passively acquired antibodies suppress humoral but not cell-mediated immunity in mice immunized with live attenuated respiratory syncytial virus vaccines.
    Crowe JE; Firestone CY; Murphy BR
    J Immunol; 2001 Oct; 167(7):3910-8. PubMed ID: 11564809
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Protection against respiratory syncytial virus by a recombinant Newcastle disease virus vector.
    Martinez-Sobrido L; Gitiban N; Fernandez-Sesma A; Cros J; Mertz SE; Jewell NA; Hammond S; Flano E; Durbin RK; García-Sastre A; Durbin JE
    J Virol; 2006 Feb; 80(3):1130-9. PubMed ID: 16414990
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Combining DNA and protein vaccines for early life immunization against respiratory syncytial virus in mice.
    Martinez X; Li X; Kovarik J; Klein M; Lambert PH; Siegrist CA
    Eur J Immunol; 1999 Oct; 29(10):3390-400. PubMed ID: 10540351
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A Recombinant G Protein Plus Cyclosporine A-Based Respiratory Syncytial Virus Vaccine Elicits Humoral and Regulatory T Cell Responses against Infection without Vaccine-Enhanced Disease.
    Li C; Zhou X; Zhong Y; Li C; Dong A; He Z; Zhang S; Wang B
    J Immunol; 2016 Feb; 196(4):1721-31. PubMed ID: 26792805
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.